Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Uranga, P. P. España, A. Capelastegui, I. Gorordo, R. Diez, A. Bilbao, C. Mar, E. Bereciartua (Galdakao, Sondika, Spain). Comparison of inflammatory response biomarkers to predict complications in hospitalized patients with community-acquired pneumonia. Eur Respir J 2011; 38: Suppl. 55, 1472

Member's Comments

No comment yet.

Related content which might interest you: The role of inflammatory parameters in the diagnosis and management of patients with community-acquired pneumonia Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Prediction of complications development and lethal outcome in patients with community-acquired pneumonia Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Local and systemic cytokine profiles in patients with non-severe and severe community-acquired pneumonia Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 The impact of patients‘ age and concomitant diseases on community-acquired pneumonia outcome Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007 Management-based risk prediction in community-acquired pneumonia by scores and biomarkers Source: Eur Respir J 2013; 41: 974-984 Year: 2013 Incidence, risk factors and outcomes of cardiovascular events in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus Year: 2009 Role of biomarkers of systemic inflammation in the prediction of mortality and/or severe complications in community adquired pneumonia Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 The clinical significance of serum and bronchoalveoalr lavage inflammatory cytokine in patients with acute respiratory failure due to severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 347s Year: 2006 Clinical outcome and prognostic factors of acute respiratory failure due to pneumocystis pneumonia in non-HIV patients Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Inflammatory biomarkers in predicting ICU admission of severe community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Pulmonary infections and sepsis Year: 2011 Another view on the prediction of outcomes in patients with community-acquired pneumonia Source: Eur Respir J 2011; 38: 991-992 Year: 2011 Another view on the prediction of outcomes in patients with community-acquired pneumonia Source: Eur Respir J 2011; 38: 992-993 Year: 2011 Impact of neutrophil function on outcomes of community-acquired pneumonia in patients with cancer Source: Eur Respir Rev 2008; 17: 83-85 Year: 2008 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Comparison of different models of azithromycin treatment of patients with no severe community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006